A researcher has retracted two 2014 papers, after discovering they had not gone through the proper approval process before being submitted.
The papers were part of a collaboration funded by the U.S. National Institutes of Health, which focused on solving protein structures. Adam Godzik, the senior author, told Retraction Watch that all papers had to be approved by a special committee before being submitted to a journal. Given the scale of the collaboration, the committee for the Joint Center for Structural Genomics (JCSG) would assess whether researchers who had made a previous contribution to the work should be added as authors.
A pharmacy journal has retracted a 2017 cancer paper after determining that the lead author forged her co-author’s signature.
Alain Li Wan Po, editor-in-chief of the Journal of Clinical Pharmacy and Therapeutics, told Retraction Watch that, after discovering the forgery,the journal lost confidence in “the integrity of the whole report,” and decided to retract it:
Our judgment was that if an author is willing to forge a signature, we cannot be sure of the integrity of the whole report and decided on the retraction.
According to Po, the paper’s lead author, Yan Wang, objected to the retraction because “she maintained that the data were accurate.” So the editors retracted the paper without her approval — but with the agreement of the author Jatinder Lamba, whose name was forged.
How did the journal discover the forged signature?
What Caught Our Attention: One would think that the corresponding author would have to be aware that they are submitting an article for publication — but apparently not, as this retraction demonstrates. The 2016 paper listed two corresponding authors — along with both of their emails and mailing addresses — but according to the retraction notice, one of them did not give consent “in any form” to the publication. Often, we see authors unaware of the use of their name when their email has been faked, but here, it’s possible the journal simply relied on the other corresponding author for all correspondence.Continue reading Caught Our Notice: How can a publication be a surprise to a corresponding author?
The authors of a 2017 paper on emotional and behavioral gaps between boys and girls have retracted the article after discovering a coding error that completely undermined their conclusions.
The revelation prompted the researchers to republish their findings in the same journal, this time with a title that flips the narrative.
The PsychJournal study, first published in March, looked at self-regulation — loosely defined as the ability to get stuff done and keep a lid on it — in boys and girls in German elementary schools. Although previous studies had found girls might do better on this front, the authors, from the University of Leipzig and New York University’s Abu Dhabi campus, initially found the opposite:
At least one disgruntled co-author has triggered the retraction of a paper presenting a novel approach to treating a rare, genetically inherited condition.
The paper concerned research on Fragile X syndrome (FXS), characterized by both intellectual and physical abnormalities, which is linked autism. A compound that passed through phase 2 clinical trials in October 2015 appeared to partially treat FXS in mice in the study, published earlier this year.
The investigation report by UC Denver, which we obtained earlier this year via a public records request, had recommended one of the two newest retractions, which appears in the journal Hepatology. The other retraction, in the Journal of Immunology, was not flagged by the report — which found, among other conclusions, that Almut Grenz had altered multiple values in research that had already been submitted for peer review.
Here’s the notice for the Journal of Immunology paper:
A cell biology journal has retracted a 2016 paper after an investigation revealed that the corresponding author failed to include two co-authors and acknowledge the funding source.
According to the retraction notice, the Journal of Cellular Physiology retracted the paper after the University of Texas, MD Anderson Cancer Center found that last author Jin Wang had omitted two researchers from the list of authors, and had also failed to acknowledge funding from the U.S. National Institutes of Health (NIH).
Psychiatry journals have retracted two papers evaluating a schizophrenia drug after a university in Japan flagged issues, such as a lack of written informed consent.
The papers—published in Human Psychopharmacology: Clinical & Experimental in 2012 and Psychiatry and Clinical Neurosciences in 2014—examined the safety and effectiveness of an antipsychotic drug in patients with schizophrenia.
According to the retraction notice in Psychiatry and Clinical Neurosciences, the ethics committee at St. Marianna University School of Medicine in Kawasaki found that “the trial included subjects who did not satisfy inclusion criteria.” For instance, not all patients provided written informed consent. But the university found no evidence for data falsification or fabrication.